[go: up one dir, main page]

WO2012003562A8 - Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués - Google Patents

Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués Download PDF

Info

Publication number
WO2012003562A8
WO2012003562A8 PCT/BR2011/000220 BR2011000220W WO2012003562A8 WO 2012003562 A8 WO2012003562 A8 WO 2012003562A8 BR 2011000220 W BR2011000220 W BR 2011000220W WO 2012003562 A8 WO2012003562 A8 WO 2012003562A8
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
compositions containing
containing substituted
antineoplastic pharmaceutical
nitroimidazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2011/000220
Other languages
English (en)
Portuguese (pt)
Other versions
WO2012003562A4 (fr
WO2012003562A1 (fr
Inventor
Renata Barbosa De Oliveira
Ricardo José Alves
Maria Betânia FREITAS MARQUES
Mônica CRISTINA DE OLIVEIRA
Cristina Duarte Vianna Soares
Lucas REIS FELÍCIO
Elaine Amaral Leite
Marcela Silva Lopes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade Federal de Minas Gerais
Original Assignee
Universidade Federal de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal de Minas Gerais filed Critical Universidade Federal de Minas Gerais
Publication of WO2012003562A1 publication Critical patent/WO2012003562A1/fr
Publication of WO2012003562A4 publication Critical patent/WO2012003562A4/fr
Anticipated expiration legal-status Critical
Publication of WO2012003562A8 publication Critical patent/WO2012003562A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques antinéoplasiques contenant un nitroimidazol substitué. Ces compositions peuvent être utilisées dans le traitement de néoplasies au stade initial ou en combinaison avec des médicaments à activité antitumorale déjà établie à des stades plus avancés de la maladie.
PCT/BR2011/000220 2010-07-07 2011-07-07 Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués Ceased WO2012003562A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI1003297-5A BRPI1003297A2 (pt) 2010-07-07 2010-07-07 composições farmacêuticas antineoplásicas contendo compostos nitroimidazóis substituìdos
BRPI1003297-5 2010-07-07

Publications (3)

Publication Number Publication Date
WO2012003562A1 WO2012003562A1 (fr) 2012-01-12
WO2012003562A4 WO2012003562A4 (fr) 2012-03-29
WO2012003562A8 true WO2012003562A8 (fr) 2013-07-04

Family

ID=45440721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000220 Ceased WO2012003562A1 (fr) 2010-07-07 2011-07-07 Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués

Country Status (2)

Country Link
BR (1) BRPI1003297A2 (fr)
WO (1) WO2012003562A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445963A1 (de) * 1962-04-06 1969-12-04 Klosa Dipl Chem Dr Josef Verfahren zur Herstellung eines neuen Imidazolderivates
US5929104A (en) * 1997-04-02 1999-07-27 Pola Chemical Industries, Inc. Method for inducing apoptosis of cancer cell
KR20030067275A (ko) * 2002-02-07 2003-08-14 주식회사 하이폭시 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제
WO2010047831A1 (fr) * 2008-10-23 2010-04-29 Nycomed Us Inc. Formulations de gel de métronidazole stables

Also Published As

Publication number Publication date
WO2012003562A4 (fr) 2012-03-29
WO2012003562A1 (fr) 2012-01-12
BRPI1003297A2 (pt) 2012-04-10

Similar Documents

Publication Publication Date Title
WO2011041462A3 (fr) Composés polycycliques utiles en tant qu'antagonistes du récepteur d'acide lysophosphatidique
EP3318564A3 (fr) Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
WO2012055567A3 (fr) Utilisation de malononitrilamides dans la douleur neuropathique
HK1212348A1 (en) Autotaxin inhibitors
WO2011060049A3 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
WO2010141768A3 (fr) Antagonistes polycycliques de récepteurs d'acide lysophosphatidique
IN2012DN02177A (fr)
IN2012DN00754A (fr)
CL2015001785A1 (es) Compuestos derivados de heterociclos nitrogenados, moduladores de quinasas; metodo de preparacion; compuesto iintermediario; composicion farmaceutica; y un metodo para tratar un sujeto que posee una enferemedad o condicion como cancer, aml, tumores estromales gastrointestinales o mastocitosis.
WO2011103202A3 (fr) Modulateurs du récepteur des androgènes et leurs utilisations
WO2015061572A8 (fr) Inhibiteurs du récepteur du facteur de croissance des fibroblastes
CR20120202A (es) Métodos y composiciones para tratar cáncer
WO2015070224A3 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
WO2012088266A3 (fr) Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
WO2012037410A3 (fr) Modulateurs des récepteurs des oestrogènes et leurs utilisations
WO2011156518A3 (fr) Modulateur du récepteur oestrogénique et utilisation de ces derniers
EP3016653A4 (fr) Composés de pyrrolo-pyrrole carbamate et composés organiques associés, compositions pharmaceutiques et leurs utilisations médicales
WO2015059463A3 (fr) Bêta-caténine
WO2012103810A1 (fr) Certaines entités chimiques, compositions et procédés
MY174883A (en) Treatment of brain cancer
EP3133073A3 (fr) Inhibiteurs d'iap
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11803033

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11803033

Country of ref document: EP

Kind code of ref document: A1